62 related articles for article (PubMed ID: 19734843)
21. Pan-Cancer Analysis of Clinical Relevance via Telomere Maintenance Mechanism.
Sung JY; Cheong JH
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681758
[TBL] [Abstract][Full Text] [Related]
22. ALT Positivity in Human Cancers: Prevalence and Clinical Insights.
MacKenzie D; Watters AK; To JT; Young MW; Muratori J; Wilkoff MH; Abraham RG; Plummer MM; Zhang D
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34069193
[TBL] [Abstract][Full Text] [Related]
23. SLX4IP and telomere dynamics dictate breast cancer metastasis and therapeutic responsiveness.
Robinson NJ; Morrison-Smith CD; Gooding AJ; Schiemann BJ; Jackson MW; Taylor DJ; Schiemann WP
Life Sci Alliance; 2020 Apr; 3(4):. PubMed ID: 32071280
[TBL] [Abstract][Full Text] [Related]
24. Breast Tissue Biology Expands the Possibilities for Prevention of Age-Related Breast Cancers.
Fresques T; Zirbes A; Shalabi S; Samson S; Preto S; Stampfer MR; LaBarge MA
Front Cell Dev Biol; 2019; 7():174. PubMed ID: 31555644
[TBL] [Abstract][Full Text] [Related]
25. Stem cells, immortality, and the evolution of metastatic properties in breast cancer: telomere maintenance mechanisms and metastatic evolution.
Robinson NJ; Taylor DJ; Schiemann WP
J Cancer Metastasis Treat; 2019; 5():. PubMed ID: 31440584
[TBL] [Abstract][Full Text] [Related]
26. Weighted correlation network analysis of triple-negative breast cancer progression: Identifying specific modules and hub genes based on the GEO and TCGA database.
Lan L; Xu B; Chen Q; Jiang J; Shen Y
Oncol Lett; 2019 Aug; 18(2):1207-1217. PubMed ID: 31423181
[TBL] [Abstract][Full Text] [Related]
27. Telomere Length Maintenance in Cancer: At the Crossroad between Telomerase and Alternative Lengthening of Telomeres (ALT).
De Vitis M; Berardinelli F; Sgura A
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29463031
[TBL] [Abstract][Full Text] [Related]
28. Telomere maintenance in soft tissue sarcomas.
Eastley N; Ottolini B; Garrido C; Shaw JA; McCulloch TA; Ashford RU; Royle NJ
J Clin Pathol; 2017 May; 70(5):371-377. PubMed ID: 28183782
[TBL] [Abstract][Full Text] [Related]
29. Life and cancer without telomerase: ALT and other strategies for making sure ends (don't) meet.
Apte MS; Cooper JP
Crit Rev Biochem Mol Biol; 2017 Feb; 52(1):57-73. PubMed ID: 27892716
[TBL] [Abstract][Full Text] [Related]
30. Comparison of telomere length and insulin-like growth factor-binding protein 7 promoter methylation between breast cancer tissues and adjacent normal tissues in Turkish women.
Kaya Z; Akkiprik M; Karabulut S; Peker I; Gullu Amuran G; Ozmen T; Gulluoglu BM; Kaya H; Ozer A
J Clin Lab Anal; 2017 Sep; 31(5):. PubMed ID: 27775181
[TBL] [Abstract][Full Text] [Related]
31. Means to the ends: The role of telomeres and telomere processing machinery in metastasis.
Robinson NJ; Schiemann WP
Biochim Biophys Acta; 2016 Dec; 1866(2):320-329. PubMed ID: 27768860
[TBL] [Abstract][Full Text] [Related]
32. The Role of ATRX in the Alternative Lengthening of Telomeres (ALT) Phenotype.
Amorim JP; Santos G; Vinagre J; Soares P
Genes (Basel); 2016 Sep; 7(9):. PubMed ID: 27657132
[TBL] [Abstract][Full Text] [Related]
33. ALTernative Telomere Maintenance and Cancer.
Dilley RL; Greenberg RA
Trends Cancer; 2015 Oct; 1(2):145-156. PubMed ID: 26645051
[TBL] [Abstract][Full Text] [Related]
34. Expression Pattern of Alternative Splicing Variants of Human Telomerase Reverse Transcriptase (hTERT) in Cancer Cell Lines Was not Associated with the Origin of the Cells.
Khosravi-Maharlooei M; Jaberipour M; Hosseini Tashnizi A; Attar A; Amirmoezi F; Habibagahi M
Int J Mol Cell Med; 2015; 4(2):109-19. PubMed ID: 26261800
[TBL] [Abstract][Full Text] [Related]
35. Immortalization of normal human mammary epithelial cells in two steps by direct targeting of senescence barriers does not require gross genomic alterations.
Garbe JC; Vrba L; Sputova K; Fuchs L; Novak P; Brothman AR; Jackson M; Chin K; LaBarge MA; Watts G; Futscher BW; Stampfer MR
Cell Cycle; 2014; 13(21):3423-35. PubMed ID: 25485586
[TBL] [Abstract][Full Text] [Related]
36. Telomere maintenance mechanisms in cancer: clinical implications.
Reddel RR
Curr Pharm Des; 2014; 20(41):6361-74. PubMed ID: 24975603
[TBL] [Abstract][Full Text] [Related]
37. The co-expression of telomerase and ALT pathway in human breast cancer tissues.
Xu B; Peng M; Song Q
Tumour Biol; 2014 May; 35(5):4087-93. PubMed ID: 24375252
[TBL] [Abstract][Full Text] [Related]
38. Telomerase-independent paths to immortality in predictable cancer subtypes.
Durant ST
J Cancer; 2012; 3():67-82. PubMed ID: 22315652
[TBL] [Abstract][Full Text] [Related]
39. Telomere length variation in normal epithelial cells adjacent to tumor: potential biomarker for breast cancer local recurrence.
Zhou X; Meeker AK; Makambi KH; Kosti O; Kallakury BV; Sidawy MK; Loffredo CA; Zheng YL
Carcinogenesis; 2012 Jan; 33(1):113-8. PubMed ID: 22072619
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes.
Heaphy CM; Subhawong AP; Hong SM; Goggins MG; Montgomery EA; Gabrielson E; Netto GJ; Epstein JI; Lotan TL; Westra WH; Shih IeM; Iacobuzio-Donahue CA; Maitra A; Li QK; Eberhart CG; Taube JM; Rakheja D; Kurman RJ; Wu TC; Roden RB; Argani P; De Marzo AM; Terracciano L; Torbenson M; Meeker AK
Am J Pathol; 2011 Oct; 179(4):1608-15. PubMed ID: 21888887
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
